Hospital
HCH Tucson Holdings LLC
HCH Tucson Holdings LLC was paid $40.95M by Medicaid between Jan 2018 and Dec 2024, across 228 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoHCH TUCSON HOLDINGS LLC
NOGALES, AZ 85621
NOGALES, AZ 85621
33aNPI1639555865assigned 08/11/2015
33bProvider typeCritical Access Hospital
28Total paid$40.95M
24GClaims606,370
24DCodes billed228
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arizona
Rank by total paid#2 of 15
Median peer was paid$6.92M
This provider vs. median5.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 95,473 | $5.37M | |
| 2019 | 102,513 | $6.06M | |
| 2020 | 75,595 | $5.41M | |
| 2021 | 83,523 | $5.87M | |
| 2022 | 93,009 | $6.48M | |
| 2023 | 86,338 | $6.26M | |
| 2024incomplete | 69,919 | $5.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 31,741 | 29,004 | $10.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 20,197 | 18,087 | $7.69M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 4,954 | 4,408 | $4.92M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 10,916 | 9,605 | $3.33M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.6% | 37,244 | 9,346 | $2.71M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.7% | 5,314 | 4,726 | $1.93M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 2,466 | 2,227 | $1.79M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.4% | 1,762 | 1,568 | $980K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 4,397 | 4,116 | $890K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.8% | 19,548 | 5,974 | $718K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 1,065 | 969 | $623K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 4,118 | 1,397 | $446K |
216 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 13,678 | $347K |
| 97162 | <1% | 1,520 | $342K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,665 | $300K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,117 | $226K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,001 | $225K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,384 | $202K |
| G0378 | Hospital observation service, per hour | <1% | 1,503 | $193K |
| 73564 | <1% | 1,593 | $182K | |
| 73030 | <1% | 1,530 | $141K | |
| 97161 | <1% | 2,246 | $140K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,562 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,589 | $102K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,706 | $99K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 768 | $98K |
| 86850 | <1% | 1,992 | $98K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,972 | $92K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 508 | $90K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 132 | $68K |
| 12001 | <1% | 155 | $66K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 987 | $65K |
| 97014 | <1% | 7,582 | $61K | |
| 76642 | <1% | 581 | $60K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,089 | $57K |
| 73630 | <1% | 1,552 | $53K | |
| 74018 | <1% | 1,707 | $52K | |
| 73610 | <1% | 1,634 | $50K | |
| 93971 | <1% | 529 | $46K | |
| 99292 | <1% | 49 | $41K | |
| 71250 | <1% | 362 | $39K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 57 | $37K |
| 73110 | <1% | 841 | $36K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 773 | $33K |
| 77080 | <1% | 517 | $33K | |
| 80053 | Comprehensive metabolic panel | <1% | 33,042 | $30K |
| 72131 | <1% | 122 | $30K | |
| 73502 | <1% | 478 | $29K | |
| 73130 | <1% | 1,002 | $28K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,138 | $28K |
| 97164 | <1% | 247 | $27K | |
| 70498 | <1% | 13 | $27K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 6,251 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,991 | $19K |
| 76770 | <1% | 149 | $18K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 926 | $17K |
| 76536 | <1% | 114 | $17K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 191 | $16K |
| 96367 | <1% | 871 | $16K | |
| 76830 | Ultrasound, transvaginal | <1% | 169 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,799 | $15K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 44 | $15K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,667 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,068 | $14K |
| 72110 | <1% | 63 | $12K | |
| 36416 | <1% | 2,060 | $11K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 16 | $11K |
| 73080 | <1% | 236 | $11K | |
| 72100 | <1% | 224 | $10K | |
| 84702 | <1% | 2,292 | $10K | |
| 80061 | Lipid panel | <1% | 1,159 | $9K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 385 | $8K |
| 73562 | <1% | 172 | $8K | |
| 29125 | <1% | 12 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,496 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,839 | $6K |
| 87070 | <1% | 2,494 | $6K | |
| 92523 | <1% | 44 | $5K | |
| 83970 | <1% | 131 | $5K | |
| 97116 | <1% | 1,087 | $5K | |
| 87186 | <1% | 3,223 | $5K | |
| 82803 | <1% | 532 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,506 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,407 | $4K |
| 87088 | <1% | 9,050 | $3K | |
| 84484 | <1% | 12,326 | $3K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $3K |
| 82728 | <1% | 411 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,610 | $2K |
| 73140 | <1% | 139 | $2K | |
| 83735 | <1% | 4,034 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,312 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,492 | $2K |
| 87040 | <1% | 3,890 | $2K | |
| 97163 | <1% | 18 | $2K | |
| 76882 | <1% | 12 | $2K | |
| 76801 | <1% | 39 | $2K | |
| 96376 | <1% | 2,880 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,161 | $1K |
| 83880 | <1% | 2,653 | $1K | |
| 86703 | <1% | 361 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 5,845 | $1K |
| 74019 | <1% | 272 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,469 | $773.68 |
| 84153 | <1% | 43 | $761.00 | |
| 51702 | <1% | 33 | $629.07 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,700 | $620.80 |
| 85379 | <1% | 2,001 | $571.04 | |
| 81001 | <1% | 22,383 | $514.34 | |
| 82043 | <1% | 45 | $503.39 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,047 | $476.95 |
| 81025 | <1% | 5,182 | $447.76 | |
| 85730 | <1% | 1,760 | $443.78 | |
| 85610 | <1% | 3,752 | $362.28 | |
| 82247 | <1% | 34 | $328.14 | |
| 97035 | <1% | 497 | $316.30 | |
| 87077 | <1% | 2,685 | $303.86 | |
| 82607 | <1% | 24 | $303.48 | |
| 84703 | <1% | 3,143 | $246.59 | |
| 86780 | <1% | 145 | $232.63 | |
| 83605 | <1% | 6,460 | $229.42 | |
| 80069 | <1% | 201 | $217.43 | |
| 84436 | <1% | 413 | $188.28 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 60 | $172.06 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,092 | $144.47 |
| 72040 | <1% | 15 | $124.31 | |
| 83690 | <1% | 10,449 | $121.23 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,566 | $120.35 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 140 | $118.75 |
| 83550 | <1% | 671 | $107.36 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,109 | $102.82 |
| 82948 | <1% | 4,764 | $99.67 | |
| 83540 | <1% | 707 | $94.63 | |
| 87899 | <1% | 78 | $79.29 | |
| 81003 | <1% | 1,628 | $64.30 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,270 | $59.57 |
| 82570 | <1% | 769 | $53.10 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,357 | $50.15 |
| 87430 | <1% | 2,052 | $44.75 | |
| 87807 | <1% | 1,535 | $41.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,498 | $36.43 |
| 86140 | <1% | 198 | $31.26 | |
| 87147 | <1% | 103 | $30.42 | |
| 90715 | <1% | 1,086 | $26.87 | |
| 86900 | <1% | 2,392 | $23.32 | |
| 86901 | <1% | 2,394 | $20.03 | |
| 96368 | <1% | 80 | $17.96 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,367 | $13.78 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 185 | $12.50 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,291 | $11.32 |
| 83615 | <1% | 796 | $10.90 | |
| 94664 | <1% | 439 | $10.68 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,908 | $10.40 |
| 85014 | <1% | 199 | $10.30 | |
| 86592 | <1% | 488 | $8.62 | |
| 85651 | <1% | 825 | $8.01 | |
| 84030 | <1% | 39 | $7.20 | |
| 85027 | <1% | 930 | $7.18 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 56 | $7.06 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,010 | $5.16 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,170 | $5.12 |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,372 | $4.65 |
| 82550 | <1% | 393 | $4.63 | |
| 84295 | <1% | 179 | $3.51 | |
| 84132 | <1% | 180 | $3.44 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,351 | $1.78 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 209 | $1.38 |
| A9270 | Non-covered item or service | <1% | 8,268 | $1.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,344 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 843 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 1,142 | $0.00 |
| 87205 | 0% | 167 | $0.00 | |
| 80320 | 0% | 981 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 72 | $0.00 |
| 88342 | 0% | 54 | $0.00 | |
| 87340 | 0% | 352 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 475 | $0.00 |
| 86762 | 0% | 312 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 62 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 14 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 13 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 255 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 52 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 141 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 273 | $0.00 |
| 97032 | 0% | 106 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 16 | $0.00 |
| 73090 | 0% | 12 | $0.00 | |
| 86803 | 0% | 15 | $0.00 | |
| 74022 | 0% | 27 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 113 | $0.00 |
| 86580 | 0% | 14 | $0.00 | |
| 97750 | 0% | 20 | $0.00 | |
| 70496 | 0% | 12 | $0.00 | |
| 87467 | 0% | 49 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 37 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 17 | $0.00 |
| 87015 | 0% | 13 | $0.00 | |
| 12002 | 0% | 12 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 308 | $0.00 |
| 87210 | 0% | 38 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 289 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 90 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 211 | $0.00 |
| 80143 | 0% | 334 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 226 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 266 | $0.00 |
| 82374 | 0% | 34 | $0.00 | |
| 84156 | 0% | 145 | $0.00 | |
| 82010 | 0% | 29 | $0.00 | |
| 84439 | 0% | 116 | $0.00 | |
| 87045 | 0% | 63 | $0.00 | |
| 87209 | 0% | 18 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 67 | $0.00 |
| 36600 | 0% | 56 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 39 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 239 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 130 | $0.00 |
| 82272 | 0% | 12 | $0.00 | |
| 12011 | 0% | 25 | $0.00 | |
| 87177 | 0% | 19 | $0.00 | |
| 82248 | 0% | 18 | $0.00 | |
| 84100 | 0% | 46 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 17 | $0.00 |
| 82947 | 0% | 15 | $0.00 | |
| 82140 | 0% | 15 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDIAL, JODY (CFO)
| Provider | Location | Paid |
|---|---|---|
| HCH Tucson Holdings LLC | Nogales, AZ | $240K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.